Featured Content |Content Library
In a clinical trial involving patients with ovarian cancer previously treated with platinum-based chemotherapy, a novel “conjugate” therapy produced a substantially better response than standard treatments. Results from this study were ...
Ursula Matulonis, MD presented results of the SORAYA study at the 2022 Society for Gynecologic Oncology Annual Meeting.
A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer. Results from this trial ...
Panos Konstantinopoulos, MD, PhD shares results of a phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or persistent endometrial cancer at the 2022 Society for Gynecologic Oncology Annual Meeting.
Receive Dana-Farber's e-newsletter, Momentum, to learn of advances in cancer research and care, current clinical trials, and upcoming CME programs.